BIO [NYSE]
Bio-Rad Laboratories, Inc.
IndexS&P 500 P/E- EPS (ttm)-4.88 Insider Own1.50% Shs Outstand29.93M Perf Week0.85%
Market Cap15.47B Forward P/E33.29 EPS next Y15.58 Insider Trans0.00% Shs Float21.47M Perf Month-2.12%
Income-101.10M PEG- EPS next Q2.95 Inst Own79.50% Short Float1.55% Perf Quarter-9.38%
Sales2.90B P/S5.34 EPS this Y11.40% Inst Trans0.33% Short Ratio1.43 Perf Half Y-31.53%
Book/sh340.19 P/B1.52 EPS next Y7.41% ROA-0.60% Target Price711.67 Perf Year-12.51%
Cash/sh69.51 P/C7.46 EPS next 5Y17.80% ROE-0.80% 52W Range468.86 - 832.70 Perf YTD-31.35%
Dividend- P/FCF33.71 EPS past 5Y176.00% ROI-5.10% 52W High-37.71% Beta0.89
Dividend %- Quick Ratio4.20 Sales past 5Y7.20% Gross Margin56.80% 52W Low10.64% ATR18.93
Employees7900 Current Ratio5.10 Sales Q/Q-3.70% Oper. Margin18.40% RSI (14)50.12 Volatility3.43% 3.75%
OptionableYes Debt/Eq0.12 EPS Q/Q-447.70% Profit Margin-3.50% Rel Volume0.90 Prev Close520.75
ShortableYes LT Debt/Eq0.12 EarningsApr 28 AMC Payout- Avg Volume232.25K Price518.73
Recom1.50 SMA203.16% SMA50-4.14% SMA200-22.73% Volume208,436 Change-0.39%
Jan-28-22Reiterated Citigroup Buy $915 → $750
Jan-08-20Initiated Wells Fargo Overweight $430
Jan-07-20Initiated Citigroup Buy $450
Oct-17-18Initiated Goldman Buy $350
Sep-20-18Initiated Morgan Stanley Equal-Weight $335
Feb-16-18Downgrade CL King Buy → Neutral
Jul-13-17Initiated Wells Fargo Outperform
Jun-28-17Upgrade Deutsche Bank Hold → Buy $220 → $255
Jan-18-17Initiated Deutsche Bank Hold $195
Oct-13-16Initiated CL King Buy
May-06-15Reiterated Jefferies Buy $150 → $165
Dec-18-09Initiated Maxim Group Buy $125
Nov-06-09Initiated Jefferies & Co Buy $130
Jul-17-09Initiated Soleil Buy $91
Sep-26-07Initiated Banc of America Sec Buy $110
Feb-23-07Downgrade Robert W. Baird Outperform → Neutral $83 → $76
May-05-22 11:24AM  
Apr-29-22 10:31AM  
Apr-28-22 05:45PM  
04:15PM  
Apr-27-22 10:52AM  
Apr-25-22 09:02AM  
Apr-21-22 05:17PM  
Apr-19-22 10:19AM  
Apr-18-22 08:00AM  
Apr-13-22 10:10AM  
09:09AM  
09:04AM  
08:54AM  
Apr-12-22 10:36AM  
Apr-11-22 12:58PM  
08:50AM  
Apr-08-22 09:53AM  
Apr-07-22 11:18AM  
09:31AM  
Apr-06-22 09:25AM  
Apr-05-22 09:09AM  
08:57AM  
Apr-04-22 09:52AM  
09:51AM  
Apr-01-22 09:15AM  
Mar-31-22 08:54AM  
Mar-30-22 11:22AM  
08:43AM  
Mar-29-22 08:59AM  
Mar-28-22 12:21PM  
09:11AM  
09:10AM  
Mar-25-22 12:54PM  
Mar-24-22 12:08PM  
10:10AM  
Mar-23-22 08:55AM  
08:47AM  
Mar-22-22 12:23PM  
09:42AM  
Mar-21-22 11:27AM  
11:25AM  
Mar-17-22 12:24PM  
12:23PM  
Mar-11-22 01:57PM  
09:14AM  
Mar-10-22 12:48PM  
12:17PM  
10:32AM  
10:24AM  
09:10AM  
Mar-09-22 10:00AM  
08:48AM  
08:48AM  
Mar-08-22 11:21AM  
Mar-07-22 08:06AM  
08:04AM  
Mar-04-22 10:52AM  
07:45AM  
Mar-03-22 11:10AM  
09:17AM  
Mar-02-22 05:51PM  
12:53PM  
10:19AM  
10:01AM  
08:51AM  
Mar-01-22 11:37AM  
09:31AM  
07:54AM  
07:52AM  
Feb-28-22 10:26AM  
10:16AM  
09:59AM  
Feb-25-22 09:15AM  
08:50AM  
08:36AM  
08:30AM  
Feb-24-22 10:40AM  
10:14AM  
10:05AM  
08:31AM  
08:27AM  
Feb-23-22 11:10AM  
11:07AM  
10:02AM  
07:53AM  
Feb-22-22 10:50AM  
Feb-21-22 09:56AM  
Feb-18-22 10:23AM  
Feb-17-22 12:20PM  
10:05AM  
08:24AM  
Feb-16-22 10:48AM  
10:21AM  
10:00AM  
Feb-15-22 12:08PM  
Feb-14-22 04:39PM  
Feb-11-22 09:14AM  
Feb-10-22 05:35PM  
04:15PM  
Feb-09-22 09:43AM  
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Last Andrew J.EVP, Chief Operating OfficerApr 29Option Exercise0.001,00002,764May 02 02:44 PM
RAMALINGAM AJITSVP, Chief Accounting OfficerApr 29Option Exercise0.002770698May 02 02:42 PM
Daskal IlanEVP, Chief Financial OfficerApr 08Option Exercise0.007000709Apr 11 12:16 PM
WRIGHT DARAExecutive Vice PresidentDec 16Option Exercise0.0050201,113Dec 17 02:21 PM
TUMOLO ANNETTEExecutive Vice PresidentNov 12Option Exercise250.214,8001,201,0149,393Nov 15 10:55 AM
TUMOLO ANNETTEExecutive Vice PresidentNov 12Sale750.054,8003,600,2404,593Nov 15 10:55 AM
TUMOLO ANNETTEExecutive Vice PresidentNov 11Option Exercise386.821,546598,0296,139Nov 15 10:55 AM
TUMOLO ANNETTEExecutive Vice PresidentNov 11Sale749.001,5461,157,9584,593Nov 15 10:55 AM
SCHWARTZ NORMAN DChairman, President, and CEOSep 07Option Exercise92.5640,0003,702,220336,786Sep 09 09:39 AM
Crowley MichaelEVP, GBL Commercial OperationsSep 07Option Exercise0.0060005,371Sep 09 09:38 AM
TUMOLO ANNETTEExecutive Vice PresidentSep 07Option Exercise0.0060004,891Sep 09 09:38 AM
ERNST TIMOTHY SEVP, General Counsel & SecSep 07Option Exercise0.0050002,401Sep 09 09:37 AM
Crowley MichaelEVP, GBL Commercial OperationsSep 05Option Exercise0.0060005,069Sep 08 12:10 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 05Option Exercise0.002,6000424,960Sep 08 12:09 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 05Option Exercise0.0060004,589Sep 08 12:06 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 05Option Exercise0.0050002,149Sep 08 12:05 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 04Option Exercise0.0060004,767Sep 08 12:10 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 04Option Exercise0.002,6000423,650Sep 08 12:09 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 04Option Exercise0.0060004,287Sep 08 12:06 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 04Option Exercise0.0050001,897Sep 08 12:05 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 03Option Exercise0.0046401,619Sep 08 12:05 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 03Option Exercise0.0055704,444Sep 08 12:10 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 03Option Exercise0.002,3190422,200Sep 08 12:09 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 03Option Exercise0.0055703,939Sep 08 12:06 PM
Daskal IlanEVP, Chief Financial OfficerSep 03Sale820.06270221,4169Sep 08 12:07 PM
Daskal IlanEVP, Chief Financial OfficerSep 02Option Exercise261.911,081283,122548Sep 03 05:02 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 02Option Exercise0.0036101,280Sep 03 05:01 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 02Option Exercise0.001,8050420,776Sep 03 05:12 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 02Option Exercise0.0043303,532Sep 03 05:10 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 02Option Exercise0.0043304,102Sep 03 05:09 PM
RAMALINGAM AJITSVP, Chief Accounting OfficerSep 02Option Exercise0.002400473Sep 03 05:07 PM
WRIGHT DARAExecutive Vice PresidentSep 02Option Exercise0.004330761Sep 03 05:08 PM
Last Andrew J.EVP, Chief Operating OfficerSep 02Option Exercise0.0090202,184Sep 03 05:05 PM
Daskal IlanEVP, Chief Financial OfficerSep 02Sale828.00540447,1217Sep 03 05:02 PM
Last Andrew J.EVP, Chief Operating OfficerSep 01Option Exercise299.242,000598,4803,282Sep 03 05:05 PM
Last Andrew J.EVP, Chief Operating OfficerSep 01Sale813.102,0001,626,2031,282Sep 03 05:05 PM
TUMOLO ANNETTEExecutive Vice PresidentAug 26Sale792.58600475,5483,099Aug 27 10:39 AM
Crowley MichaelEVP, GBL Commercial OperationsAug 09Option Exercise139.563,000418,6806,669Aug 10 11:58 AM
Crowley MichaelEVP, GBL Commercial OperationsAug 09Sale754.933,0002,264,7963,669Aug 10 11:58 AM
Daskal IlanEVP, Chief Financial OfficerAug 04Option Exercise309.841,400433,7762,307Aug 05 12:38 PM
ERNST TIMOTHY SEVP, General Counsel & SecAug 04Sale760.26327248,605919Aug 05 12:40 PM
Daskal IlanEVP, Chief Financial OfficerAug 04Sale751.842,3001,729,2417Aug 05 12:38 PM